经皮股动脉植入导管药盒系统治疗转移性肝癌

目的 探讨经皮股动脉植入导管药盒系统的临床疗效。方法 30例转移性肝癌采用经皮股动脉植入导管药盒系统。依据肿瘤供血特点 ,在透视监控下 ,施行导管药盒系统植入式。结果 CR3例、PR1 4例、CR+PR5 6 .7% ,半年生存率 1 0 0 % ,1年生存率 5 3.3% (1 6 / 30 ) ,2年生存率1 6 .7% (5 / 30 ) ,无 1例严重并发症发生。结论 经皮股动脉植入导管药盒系统治疗转移性肝癌是安全可行 ,有效的。

经皮股动脉导管药盒系统植入术的并发症及临床处理

目的 探讨经股动脉导管药盒系统植入术 (PCS)的并发症原因及处理。方法 2 0 2例胸、腹、盆腔及四肢恶性肿瘤采用经皮股动脉植入PCS进行化疗和碘油栓塞。分析其相关并发症 35例(17.3%)。结果 并发症包括 6例切口感染及切口延迟愈合 (17.1%) ,2例穿刺局部延迟出血 (5 .7%) ,3例PCS留置管坠落 (8.6 %) ,1例连接不牢分离 (2 .9%) ,1例渗漏 (2 .9%) ,1例药盒转面 (2 .9%) ,11例PCS堵塞 (31.4 %)和 10例留置导管尖移位 (2 8.6 %)。所有并发症经适当处理后无一例死亡和严重后遗症。结论 经皮股动脉药盒系统植入术是一种安全有效技术 ,其相关并发症轻微和易于处理。

经皮经股动脉植入药盒系统治疗晚期胃癌的临床疗效

目的 探讨药盒在晚期胃癌治疗中的临床价值。方法 无法外科手术的胃癌 18例 ,依据化疗途径不同分两组 :A组 10例 ,采用经皮经股动脉植入药盒 ,术后经药盒 1周或 2周化疗 1次 ,B组 8例 ,采用术中动脉插管化疗 ,每 1周或 2周化疗 1次。结果 A、B两组有效率 (CR +PR)分别为 5 0 %和 37 5 %(P <0 0 5 ) ,A组 6个月、1年、2年生存率分别为 10 0 %、5 0 %、2 0 %,B组分别为 75 %、37 5 %、12 5 %(P <0 0 1) ,A组患者的生存质量明显改善 ,消化道反应、肝胆骨髓毒性均较B组低。结论 经药盒间断性化疗治疗晚期胃癌可明显改善患者的生存质量 ,提高生存率。

Interventional and synthetic therapy of advanced hepatocellular carcinoma

OBJECTIVE: To evaluate the clinical efficacy of interventional therapy in the treatment of hepatocellular carcinoma (HCC). METHODS: Thirty-three patients with HCC were synthetically treated by systematic measures. Among them, percutaneous port-catheter system (PCS) implantation via the femoral artery was performed in 21 cases. Patients with haemorrhage were treated with prothrombin complex concentrate and fibroraas, and patients with hepatic encephalopathy by branched-chain amino acids and arginine. RESULTS: All indwelling catheters of PCS were patent and no catheter tip dislocations were observed. Of 33 patients with advanced HCC, the mean survival rate was 20.1 months and 12 (36%) patients survived more than 2 years. CONCLUSION: Patients with advanced HCC were treated by synthetic measures. Survival was prolonged, quality of life was improved significantly, and the effectiveness of interventional therapy was further improved.